Kimberly Struble, PharmD, is a Senior Clinical Team Leader in the Division of Antiviral Products at the Food and Drug Administration. She provides expertise in all phases of antiviral clinical drug development and leads a team responsible for the development of new products for the treatment and prevention of HIV infection, hepatitis B and C, influenza, various herpes infections, and other emerging viral infections. She was a co-princple investigator for a grant from FDA’s Office of Women’s Health regarding efficacy and safety gender issues for HIV antiretroviral agents. She is a member of the Department of Health and Human Services HIV Treatment Guidelines Panel. She serves on various HIV-related committees including the executive committees for the Forum for Collaborative HIV Research and Long-Acting/Extended Release Antiretroviral Drugs (LEAP). She is also the FDA representative to CDC for occupational and nonoccupational post-exposure prophylaxis public health service working group. She has over 20 publications and 50 presentations relating to HIV and HCV drug development and FDA regulations.
Conflict of Interest: None disclosed.